Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1246 | Experimental 2 Wiki | 0.38 |
| drug1559 | Hydroxychloroquine plus standard preventive measures Wiki | 0.38 |
| drug3883 | exposure Wiki | 0.38 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1245 | Experimental 1 Wiki | 0.38 |
| drug726 | Cannabis, Medical Wiki | 0.38 |
| drug2559 | Placebo plus standard preventive measures Wiki | 0.38 |
| drug2211 | No Intervention - Observational Study Wiki | 0.38 |
| drug3590 | Unsupervised physical activities Wiki | 0.38 |
| drug2743 | Questionnaire and interview Wiki | 0.38 |
| drug3645 | Video Dance classes Wiki | 0.38 |
| drug422 | BNT162b2 Wiki | 0.27 |
| drug421 | BNT162b1 Wiki | 0.22 |
| drug2505 | Placebo Wiki | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D000070627 | Chronic Traumatic Encephalopathy NIH | 0.38 |
| D009069 | Movement Disorders NIH | 0.38 |
| D003291 | Conversion Disorder NIH | 0.38 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D005879 | Tourette Syndrome NIH | 0.38 |
| D006816 | Huntington Disease NIH | 0.27 |
| D000690 | Amyotrophic Lateral Sclerosis NIH | 0.27 |
| D000755 | Anemia, Sickle Cell NIH | 0.27 |
| D016472 | Motor Neuron Disease NIH | 0.27 |
| D001714 | Bipolar Disorder NIH | 0.27 |
| D012640 | Seizures NIH | 0.22 |
| D005356 | Fibromyalgia NIH | 0.19 |
| D001927 | Brain Diseases NIH | 0.19 |
| D015212 | Inflammatory Bowel Diseases NIH | 0.14 |
| D000070642 | Brain Injuries, Traumatic NIH | 0.13 |
| D004194 | Disease NIH | 0.12 |
| D003424 | Crohn Disease NIH | 0.12 |
| D001930 | Brain Injuries, NIH | 0.11 |
| D059350 | Chronic Pain NIH | 0.11 |
| D012598 | Scoliosi NIH | 0.10 |
| D009103 | Multiple Sclerosis NIH | 0.10 |
| D020521 | Stroke NIH | 0.09 |
| D040921 | Stress Disorders, Traumatic NIH | 0.07 |
| D014947 | Wounds and Injuries NIH | 0.07 |
| D013313 | Stress Disorders, Post-Traumatic NIH | 0.06 |
| D013577 | Syndrome NIH | 0.04 |
| D003141 | Communicable Diseases NIH | 0.03 |
| D007239 | Infection NIH | 0.02 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.02 |
| D018352 | Coronavirus Infections NIH | 0.01 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0006802 | Abnormal anterior horn cell morphology HPO | 0.38 |
| HP:0007354 | Amyotrophic lateral sclerosis HPO | 0.38 |
| HP:0100754 | Mania HPO | 0.27 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001250 | Seizure HPO | 0.22 |
| HP:0001298 | Encephalopathy HPO | 0.19 |
| HP:0002037 | Inflammation of the large intestine HPO | 0.14 |
| HP:0012532 | Chronic pain HPO | 0.13 |
| HP:0100280 | Crohn's disease HPO | 0.12 |
Navigate: Correlations HPO
There are 7 clinical trials
The objective of this study is to evaluate the cortisol awakening response with persons with Parkinsons Disease (PD), Huntingtons Disease (HD), and controls. These data are desired so experience can be gained with measuring stress levels subjectively and objectively in persons with PD, HD, and controls.
Description: Salivary Cortisol level (ug/dL) Response is the change in cortisol between awakening and 30 minutes after awakening.
Measure: Awakening Salivary Cortisol level (ug/dL) Response Time: Collected upon awakening and 30 minutes after awakeningThis will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.
Description: Covid-19 infection rates in cannabis users will be compared to rates in the general population. Our online questionnaire responses will compare infection rates of cannabis users in this study against the Johns Hopkins University Coronavirus Research Center data (https://coronavirus.jhu.edu).
Measure: Prevention of COVID-19 Time: Five yearsDescription: Severity of persistent symptoms in cannabis users testing positive for active infection and/or antibodies will also be compared to the general population. Patients will answer the widely used FLU-PRO questionnaire, which asks about flu symptoms and severity, to capture diagnoses, symptoms, and medical interventions related to COVID-19. The data from cannabis user patients will be compared with national and international data surveys, such as the Covid Symptom Study (https://covid.joinzoe.com/us-2).
Measure: Treatment of COVID-19 Time: Five yearsDescription: The primary objective is to assess the efficacy and safety of medical cannabis as medicine for treatment of chronic pain and other chronic debilitating diseases. Pain will be measured by Brief Pain Inventory (BPI) numeric scale. Change from baseline in BPI will be assessed at 3-month intervals. For prospective associations between cannabis use and outcomes, use of a lagged mixed-effects models will examine temporal associations between cannabis use and pain severity, opioid sparing, and patient satisfaction. Data will be analyzed from baseline and the annual follow-up waves.
Measure: Treatment of Symptoms Time: Five yearsDescription: Secondary objectives include evaluating increases or decreases in quality of life, and increases or decreases in concomitant opioid use. Satisfaction with treatment will be measured by a Visual Analog Score (VAS). Change From baseline in Satisfaction with treatment measured by (VAS) be assessed at 3-month intervals.
Measure: Cannabis Impact on Quality of Life Time: Five yearsDescription: Tertiary objectives will examine preferences for routes of administration, and preferences for THC / CBD ratios. Categorical factors will be summarized using frequencies and percentages, while continuous measure distributions will be described using means, standard deviations, and quartiles of interest.
Measure: Cannabis Route and Dosing Time: Five yearsDescription: Incidence of Treatment-Related Adverse Events will be measured by Physician Global Assessment (PGA) numeric scale. Number of participants with Treatment-Related Adverse Events will be assessed by CTCAE v4.0.
Measure: Monitoring Adverse Events Time: Five yearsThe aim of this study is to analyze the impact of video dance class and unsupervised physical activity on clinical-functional parameters, self-isolation and non-motors symptoms in people with Parkinson's disease during the Covid-19 pandemic.
Description: The quality of life (QoL) will be measured by the Parkinson's Disease Quality of life (PDQ-8). PDQ-8 is a reduced version of a specific health status questionnaire comprising 39 items, with 8 items. Respondents are requested to affirm one of five ordered response categories according to how often, due to their PD, they have experienced the problem defined by each item. Each item is grouped into eight scales that are scored by expressing summed item scores as a percentage score ranging between 0 and 100 (100¼more health problems).
Measure: Quality of life (QoL) Time: Change from baseline at 12 weeks.Description: This outcome will be measure for the Geriatric Depression Scale - 15 item. The scale consists of 15 dichotomous questions in which participants are asked to answer yes or no about how they felt over the past week (for instance, "Do the patient feel that their life is empty?," Do the patient feel that their situation is hopeless?). Scores range from 0 to 15 with higher scores indicating more depressive symptoms.
Measure: Depressive symptoms - Geriatric Depression Scale - 15 item Time: Change from baseline at 12 weeks.Description: This outcome will be measure for the International Physical Activity Questionnaires (IPAQ). The IPAQ comprises a set of 4 questionnaires. Long (5 activity domains asked independently) and short (4 generic items) versions for use by either telephone or self-administered methods are available. The purpose of the questionnaires is to provide common instruments that can be used to obtain internationally comparable data on health-related physical activity.
Measure: Physical Activity - International Physical Activity Questionnaires (IPAQ) Time: Change from baseline at 12 weeks.Description: Montreal Cognitive Assessment (MoCA) is a brief screening tool for mild cognitive impairment. This evaluation accesses different cognitive domains and investigates the individual's abilities in the following areas: attention and concentration, executive functions, memory, language, visuoconstructive skills, conceptualization, calculation, and orientation. The total score of the MoCA is 30 points, with a score of 26, or more, considered normal and less than 26 is considered a cognitive impairment.
Measure: Cognitive function - Montreal Cognitive Assessment by telephone Time: Change from baseline at 12 weeks.Description: This outcome will be measure for the Falls - Falls Efficacy Scale - International (FES-I). FES-I can be administered as self-completion questionnaires, or administered verbally as part of a research interview or clinical assessment. To calculate the FES-I score when all items are completed, simply add the scores for each item together to give a total that ranges as follows: minimum 16 (no concern about falling) to maximum 64 (severe concern about falling).
Measure: Falls - Falls Efficacy Scale - International Time: Change from baseline at 12 weeks.Description: The Five Times Sit to Stand Test measures one aspect of transfer skill. This test quantifies functional lower extremity strength and identifies movement strategies a people use to complete the transitional movement.
Measure: Functional lower extremity strength -Five Times Sit to Stand Test Time: Change from baseline at 12 weeks.The consequences of COVID-19 in these already fragile patients should be evaluated. It will be important to appreciate the confinement consequences imposed on the patient on the course and impact of the disease. These consequences can be assessed by the end of confinement and 6 months after the latter is lifted.
Description: To compare quality of life using Parkinson Disease Questionnaire-8 Items (PDQ-8 ), during the period of confinement linked to the Covid-19 pandemic and 6 months after the end of the pandemic in patients with idiopathic Parkinson's disease. The minimum value is "never" and maximum value is "always"
Measure: Impact of containment related to the Covid-19 pandemic. Time: 6 months after the end of the pandemicDescription: Describe in a cohort of Parkinson's patients the conditions of confinement during the confinement period linked to the Covid-19 pandemic such as lifestyle (patient living alone, patient living with a caregiver, patient living in nursing home) and continuing paramedical care (physiotherapist, speech therapist), thanks to a psychosocial assessment
Measure: Conditions of containment during the Covid-19 pandemic. Time: Day 1Description: Infected patients will be defined as having had a positive polymerase chain reaction (PCR) or compatible chest scanner. Patients potentially infected: patients who presented symptoms during the period which could suggest an infection by the Covid-19 virus: cough, fever and dyspnea
Measure: The number of patients infected or possibly infected with Covid-19 Time: 6 months after the end of the pandemicDescription: Patients will be asked to list the 3 main symptoms that have changed during the confinement period
Measure: Symptoms modifications Time: 6 months after the end of the pandemicThis study is a single-site, double-blinded, placebo-controlled, randomized clinical trial designed to elucidate mechanism(s) of action for symptomatic benefits observed in Parkinson's disease (PD) patients treating twice daily time-varying caloric vestibular stimulation treatment using a solid-state device. Study participants will self-administer treatments in the home setting over a period of 12 weeks. Changes in cerebral blood flow perfusion, cerebrovascular reactivity and functional connectivity between the pre-treatment baseline and the end of the treatment period will be monitored and will be compared to changes in validated standardized clinical measures of motor and non-motor symptoms in PD. The durability of effects will be evaluated at a post-treatment assessment conducted five weeks after treatment cessation.
Description: Brain data will be acquired with Siemens MAGNETOM Skyra 3T MRI - range measured by statistically significant change in cerebral blood flow (CBF) measured in units of mL/100g/min
Measure: Neuroimaging Time: BaselineDescription: Brain data will be acquired with Siemens MAGNETOM Skyra 3T MRI - range measured by statistically significant change in cerebral blood flow (CBF) measured in units of mL/100g/min
Measure: Neuroimaging Time: Week 12Description: Brain data will be acquired with Siemens MAGNETOM Skyra 3T MRI - range measured by statistically significant change in cerebral blood flow (CBF) measured in units of mL/100g/min
Measure: Neuroimaging Time: Week 17Description: Non-invasive ultrasound used to examine blood circulation within the brain - range measured by statistically significant change in mean cerebral blood flow velocity (cm/s)
Measure: Transcranial Doppler Sonography Time: BaselineDescription: Non-invasive ultrasound used to examine blood circulation within the brain - range measured by statistically significant change in mean cerebral blood flow velocity (cm/s)
Measure: Transcranial Doppler Sonography Time: Week 12Description: Used to follow the longitudinal course of symptoms of Parkinson's disease - Each parkinsonian sign or symptom is rated on a 5-point Likert-type scale (ranging from 0 to 4), with higher scores indicating more severe impairment. The maximum total UPDRS score is 199, indicating the worst possible disability from PD
Measure: MDS-Unified Parkinson's Disease Rating Scale Time: Baseline, Week 12, Week 17Description: To determine fall risk and measure the progress of balance, sit to stand and walking (ranging from ≤10 seconds as normal to 30 seconds as high fall risk).
Measure: Timed Up and Go Test Time: Baseline, Week 12, Week 17Description: Cognitive screening test - range from zero to 30, with a score of 26 and higher generally considered normal.
Measure: Montreal Cognitive Assessment Time: Baseline, Week 12, Week 17Description: Scale to assess a wide range of non-motor symptoms in patients with Parkinson's disease - 30-item rater-based scale to assess a wide range of non-motor symptoms in patients with Parkinson's disease (PD). The NMSS measures the severity and frequency of non-motor symptoms across nine dimensions - the total NMSQuest score significantly increased with disease severity and duration meaning that the number of individual non-motor symptoms reported by our patients increases as the disease progresses.
Measure: Non-Motor Symptom Scale Time: Baseline, Week 12, Week 17Description: A self-report measure of depression in older adults - Scores of 0-4 are considered normal, depending on age, education, and complaints; 5-8 indicate mild depression; 9-11 indicate moderate depression; and 12-15 indicate severe depression.
Measure: Geriatric Depression Scale Time: Baseline, Week 12, Week 17Description: Anxiety assessment - The PAS is a 12-item observer or patient-rated scale with three subscales, for persistent, episodic anxiety and avoidance behavior - There is a maximum total score of 48. Higher scores indicate great experiences of anxiety.
Measure: Parkinson's Anxiety Scale Time: Baseline, Week 12, Week 17Description: A self-administered questionnaire to assess the daytime sleepiness - The ESS score (the sum of 8 item scores, 0-3) can range from 0 to 24. The higher the ESS score, the higher that person's average sleep propensity in daily life (ASP), or their 'daytime sleepiness'.
Measure: Epworth Sleepiness Scale Time: Baseline, Week 12, Week 17Description: A tool to help manage chronic illness - The responses to the 13 items on the FACIT fatigue questionnaire are each measured on a 4-point Likert scale. Thus, the total score ranges from 0 to 52. High scores represent less fatigue
Measure: Functional Assessment of Chronic Illness Therapy - Fatigue - Time: Baseline, Week 12, Week 17The study aimed at describing the effects of the COVID-19 social distancing on function, health and well-being of patients with Parkinson's disease or post-stroke, and test the association between the patient activation level and these effects.An anonymous survey was distributed through social media and patient associations.Community-living patients with Parkinson's disease or post-stroke were invited to answer the survey.
Description: The PAM is a self-reported validated, licensed tool to measure a patient's knowledge, skills and confidence for self-management. The overall score captures the extent to which people feel engaged and confident in taking care of their health condition. It consists of 13 statements rated on a Likert scale according to agreement. Scores are divided into 4 levels, where 1 represents patients who tend to be passive and feel overwhelmed managing their own health, and 4 represents patients who have effectively adopted self-management behaviors. We used a validated licensed Hebrew and version of the PAM supplied by Insignia Health (https://www.insigniahealth.com/products/pam-survey), which holds the copyright to the questionnaire.
Measure: Patient Activation Measure (PAM®) Time: 1 hourDescription: participants were asked to answer 27 multiple-choice questions regarding status and change in status of mobility, mood (depression, anxiety), tiredness, social support, body weight, physical activity, rehabilitative treatments and disease symptoms
Measure: Answers to multiple-choice questions Time: 1 hourThe purpose of this study is to investigate the clinical correlates of the effects of the COVID-19 pandemic on patients with Functional movement disorder (FMD) and Parkinson s Disease (PD). Primary objectives: To evaluate the change in neurological symptoms domain of the survey between pre and post-COVID 19 in FMD and PD patients. Secondary objectives: - To evaluate the change in total score of the survey between pre and post COVID 19 in FMD and PD patients - To evaluate the change in other symptom domains of the survey between pre and post COVID 19 in FMD and PD patients. Domains include: Mood/Energy, sleep, symptoms of abnormal movements related or unrelated to primary disease, physical health and exercise related change Exploratory objectives: - To evaluate whether there is a modifying effect of disease group in the changes in total score or symptom domains - To evaluate whether there is a relationship between disease severity and changes in total score or symptom domains - To evaluate whether there is a correlation between changes across symptom domains - To evaluate whether there is a correlation in raw score across symptom domains within each period Research Methods: Data will be solely collected through the use of online instruments via CiSTAR as a designed questionnaire. Questionnaire items A questionnaire aimed at determining the effects of the COVID 19 pandemic and subsequent isolation on functional state of patients with FMD and PD. The questionnaire items include: Items investigating Mood/Energy before and after COVID 19 out break Items investigating Sleep habits before and after COVID 19 out break Items investigating Neurological symptoms before and after COVID 19 out break Items investigating daily functioning before and after COVID 19 out break Items investigating Exercise habits before and after COVID 19 out break No questionnaire items will be actionable , which are items that would identify an imminent risk for participant safety requiring urgent and immediate medical or psychiatric
Description: Change in neurological symptoms domain of the survey between pre and post COVID 19 in FMD and PD patients.
Measure: Change in neurological symptoms domain of the survey between pre and post COVID 19 in FMD and PD patients. Time: December 2021Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports